Science
Mechanism of Action
SH-OLIGOPEPTIDE-1 operates by specifically binding to the epidermal growth factor receptor (EGFR) on skin cells, initiating a cascade of cellular activities. This interaction promotes cell survival, differentiation, and proliferation, thereby accelerating the skin's natural regeneration processes. It enhances microcirculation, encourages the secretion of rejuvenating factors, and significantly increases the proliferation of keratinocytes, endothelial cells, and fibroblasts crucial for skin repair. The peptide also helps modulate inflammatory responses, aids in scar reduction, fortifies the skin barrier, and provides sustained hydration. By boosting the production of essential extracellular matrix components such as collagen, elastin, and hyaluronic acid, it contributes to enhanced skin elasticity, minimized wrinkle appearance, and a more uniform complexion.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 A systematic review noted that 73% of subjects experienced a decrease in melasma after 8 weeks of applying a topical EGF serum twice daily.
- 02 A 6-week study with 20 subjects showed a 33.5% reduction in inflammatory acne lesions on the EGF-treated side of the face.
- 03 A 2012 study on a bioengineered EGF serum demonstrated statistically significant improvements in fine lines, rhytids, skin texture, pore size, and various dyschromatic conditions within one month, with sustained benefits over three months.
- 04 Multiple clinical trials indicate its efficacy in supporting wound healing for diabetic patients after laser treatment and in managing Senile purpura.
Transparency
Dusting Analysis
The Formula
Formulation
Safety
Safety Profile
While generally considered safe due to its natural presence in the body and biodegradability, SH-OLIGOPEPTIDE-1, as a 'growth factor,' carries notable cautions. EGF signaling is prevalent in many tumor cells, and while experts agree it is mitogenic (stimulates cell proliferation) rather than mutagenic (does not alter cells to be cancerous), it could potentially encourage the spread of *existing* cancerous cells. Therefore, individuals with a history of excessive UV exposure, numerous moles, skin cancer risk factors, or psoriasis should exercise caution. Regulatory bodies classify 'active EGF' as a potent, unauthorized drug, separate from cosmetic sh-oligopeptide-1. Concerns exist regarding the scientific basis of some cosmetic clinical studies and the unknown long-term risks, given its authorization as a cosmetic without proven preclinical bioactivity. The CIR status for this specific recombinant peptide is unknown; however, SkinSAFE categorizes sh-Oligopeptide-1 as 'Irritant Free'.
Your Skin
Skin Compatibility
Our Assessment
Verdict
This potent peptide demonstrates significant efficacy in promoting skin regeneration and addressing multiple signs of aging; however, its use requires careful consideration of potential growth factor implications and ongoing research into long-term safety.
Related
Similar Ingredients
Finding similar ingredients…